Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuel Comabella

Showing results (111-120 of 263) with videos related to

Pageof 27
Sort By:
Brain : a Journal of Neurology|March 19, 2010
Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosisManuel Comabella, Marta Fernández, Roland Martin, et al.
Archives of Neurology|November 16, 2011
Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-upCarmen Tur, Xavier Montalban, Mar Tintoré, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 7, 2014
Interferon-beta affects mitochondrial activity in CD4+ lymphocytes: Implications for mechanism of action in multiple sclerosisAiden Haghikia, Simon Faissner, Derek Pappas, et al.
Nature Medicine|February 18, 2014
FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MSYawei Liu, Robert Carlsson, Manuel Comabella, et al.
The American Journal of Pathology|August 18, 2014
Nerve conduction velocity is regulated by the inositol polyphosphate-4-phosphatase II geneSusanne Lemcke, Susen Müller, Steffen Möller, et al.
Journal of Neurology|September 18, 2014
N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosisAlessandro Trentini, Manuel Comabella, Mar Tintoré, et al.
Frontiers in Immunology|May 13, 2026
A glial oxidative signature predicts disability in primary progressive multiple sclerosis and is associated with long-term cognitive declineAlbert Miguela, Joana Maria Huertas-Pons, Clàudia Coll-Martinez, et al.
Clinical Immunology (Orlando, Fla.)|October 24, 2008
Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosisManuel Comabella, Jordi Río, Carmen Espejo, et al.
Journal of Neuroimmunology|December 4, 2014
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysisSteffi Grey Née Cotte, Anke Salmen Née Stroet, Nico von Ahsen, et al.
Frontiers in Immunology|May 21, 2020
A Polymorphism Within the <i>MBP</i> Gene Is Associated With a Higher Relapse Number in Male Patients of Multiple SclerosisLaura Espino-Paisán, Teresa Agudo-Jiménez, Isabel Rosales-Martínez, et al.
Pageof 27

Showing results (111-120 of 263) with videos related to

Sort By:
Pageof 27
Brain : a Journal of Neurology|March 19, 2010
Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosisManuel Comabella, Marta Fernández, Roland Martin, et al.
Archives of Neurology|November 16, 2011
Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-upCarmen Tur, Xavier Montalban, Mar Tintoré, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 7, 2014
Interferon-beta affects mitochondrial activity in CD4+ lymphocytes: Implications for mechanism of action in multiple sclerosisAiden Haghikia, Simon Faissner, Derek Pappas, et al.
Nature Medicine|February 18, 2014
FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MSYawei Liu, Robert Carlsson, Manuel Comabella, et al.
The American Journal of Pathology|August 18, 2014
Nerve conduction velocity is regulated by the inositol polyphosphate-4-phosphatase II geneSusanne Lemcke, Susen Müller, Steffen Möller, et al.
Journal of Neurology|September 18, 2014
N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosisAlessandro Trentini, Manuel Comabella, Mar Tintoré, et al.
Frontiers in Immunology|May 13, 2026
A glial oxidative signature predicts disability in primary progressive multiple sclerosis and is associated with long-term cognitive declineAlbert Miguela, Joana Maria Huertas-Pons, Clàudia Coll-Martinez, et al.
Clinical Immunology (Orlando, Fla.)|October 24, 2008
Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosisManuel Comabella, Jordi Río, Carmen Espejo, et al.
Journal of Neuroimmunology|December 4, 2014
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysisSteffi Grey Née Cotte, Anke Salmen Née Stroet, Nico von Ahsen, et al.
Frontiers in Immunology|May 21, 2020
A Polymorphism Within the <i>MBP</i> Gene Is Associated With a Higher Relapse Number in Male Patients of Multiple SclerosisLaura Espino-Paisán, Teresa Agudo-Jiménez, Isabel Rosales-Martínez, et al.
Pageof 27